Congress funds biosecurity screening standards for synthetic DNA
H.R. 3029 — Nucleic Acid Standards for Biosecurity Act · Filed by Andrea Salinas (D-OR) · 3 cosponsors · Introduced Apr 28, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal research law to direct the National Institute of Standards and Technology (NIST) to develop best practices, technical standards, and screening tools for nucleic acid synthesis—the process of creating DNA and RNA sequences. It requires NIST to convene industry, universities, and nonprofits to establish consensus standards for screening synthetic nucleic acids before they are sold or used, with the goal of preventing misuse of biotechnology for harmful purposes. The bill authorizes $5 million per year from 2027–2031 for this research.
Why we flagged it
The bill's core function is to fund NIST research into nucleic acid synthesis screening standards and best practices. It is a straightforward public-health and biosecurity measure, not a deregulation, subsidy, or liability shield.
What the text implies
- The consortium structure (industry + academia + nonprofits) may create de facto private standard-setting authority; if industry participants dominate, screening standards could be shaped to favor larger firms with compliance resources over smaller biotech startups.
- The bill does not establish enforcement mechanisms or penalties for non-compliance with screening standards, leaving implementation voluntary—effectiveness depends on downstream regulatory adoption by agencies not named in this bill.
The full analysis lists 3 implications of this text.
Who stands to gain
nucleic acid synthesis companies (DNA/RNA suppliers); biotechnology firms with compliance infrastructure; institutions of higher education (consortium participation)